Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-08-13

Last Posted Date: 2013-08-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 77

Registration Number: NCT01921478

A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)

Completed

Conditions: Down Syndrome

First Posted Date: 2013-08-12

Last Posted Date: 2017-07-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 135

Registration Number: NCT01920633

Locations: 🇪🇸
IMIM, Human Pharmacology and Clinical Neurosciences,, Barcelona, Spain
🇺🇸
Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 19 locations

U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2013-08-07

Last Posted Date: 2018-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 226

Registration Number: NCT01918267

Locations: 🇳🇱
St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands
🇳🇱
University Medical Centre Utrecht; Reumatologie en Klinische Immunologie, Utrecht, Netherlands
🇳🇱
Maartenskliniek Woerden, Woerden, Netherlands

and more 16 locations

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Pertuzumab
Drug: Lumretuzumab

First Posted Date: 2013-08-07

Last Posted Date: 2017-09-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 66

Registration Number: NCT01918254

Locations: 🇫🇷
Institut Curie; Oncologie Medicale, Paris, France
🇩🇪
Universitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany
🇪🇸
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain

and more 10 locations

A Study of RO6870868 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: placebo
Drug: RO6870868

First Posted Date: 2013-07-30

Last Posted Date: 2018-07-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT01911611

A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Drug: Vemurafenib

First Posted Date: 2013-07-29

Last Posted Date: 2019-05-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT01910181

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
Sun Yet-sen University Cancer Center, Guangzhou, China

A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis

Completed

Conditions: Muscular Atrophy, Spinal

First Posted Date: 2013-07-29

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 36

Registration Number: NCT01910168

A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Chlorambucil
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Obinutuzumab

First Posted Date: 2013-07-23

Last Posted Date: 2019-10-28

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 979

Registration Number: NCT01905943

Locations: 🇧🇷
Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil
🇧🇷
Hospital de Cancer de Barretos, Barretos, SP, Brazil
🇧🇷
Hospital Amaral Carvalho, Jau, SP, Brazil

and more 171 locations

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Phase 1

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2013-07-22

Last Posted Date: 2017-11-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT01904292

Locations: 🇺🇸
Hackensack University Medical Center; Pediatric Rheumatology, Hackensack, New Jersey, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago; Division of Rheumatology, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Fndn, Cleveland, Ohio, United States

and more 39 locations

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Phase 1

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Tocilizumab

First Posted Date: 2013-07-22

Last Posted Date: 2017-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 52

Registration Number: NCT01904279

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy